DocGo Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
DocGo Inc. (DCGO) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$69.48 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-17
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$206.08K, a 164.86% decline year-over-year.
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $317.74K.
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$103.06K, a 161.29% decline year-over-year.
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $168.15K.
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $595.80K.
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$190.64K, a 117.43% decline from fiscal 2023.
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $1.09M, a 43.67% increase from fiscal 2022.
- DocGo Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $761.23K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$69.48K 10-Q · filed 2026-08-17 | |||
| 2026-03-31 | -$206.08K 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $595.80K 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $314.14K 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $968.13K 10-Q · filed 2026-08-17 | |||
| 2025-03-31 | $317.74K 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$190.64K 10-K · filed 2026-03-16 | |||
| 2024-09-30 | $510.44K 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | -$74.53K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$103.06K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $1.09M 10-K · filed 2026-03-16 | |||
| 2023-09-30 | $227.89K 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $685.08K 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $168.15K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $761.23K 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$252.85K 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | $4.57K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | -$21.41K 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B | ||
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| GeneDx Holdings Corp. (WGS) | United States | $2.638B | -19.23 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |